LabCorp Western Blot Policy: What Changed and Why It Matters

When LabCorp Restricted Western Blot Access

In 2014, LabCorp announced a policy change that sent shockwaves through the Lyme disease community: physicians would no longer be able to order Western blot testing for Lyme disease unless the initial screening test (ELISA or IFA) was positive or equivocal.

This meant that if a patient’s screening test came back negative—even when clinical suspicion remained high—the Western blot would be automatically denied. For physicians treating Lyme disease in endemic areas, this represented a significant barrier to accurate diagnosis.

---

Why Physicians Were Ordering Western Blots Independently

Physicians had good clinical reasons for ordering Western blot testing even when screening tests were negative or not yet performed.

The sensitivity of whole-cell ELISA testing for patients presenting with erythema migrans (EM rash) typically falls between 33-49%. The FDA-approved C6 peptide test showed 37% sensitivity in clinically well-defined Lyme disease cases and 66.5% sensitivity in patients with EM rash.

These numbers meant that screening tests missed more than half of genuine early Lyme cases.

Western blot testing provided additional diagnostic information. IgM Western blot can persist for at least 2 years in individuals with established Lyme disease infection—even after antibiotic treatment. IgG Western blot can be positive in individuals with negative screening tests, capturing cases that would otherwise be missed.

For clinicians experienced in tick-borne illness, the Western blot was not just a confirmation test—it was often the only way to document infection when screening tests failed.

---

Why Testing Access Was Restricted

LabCorp’s decision reflected broader concerns about Western blot testing that had been building in the diagnostic community.

Technical Complexity and Variability

Western blot requires visual interpretation of antibody bands. Results can vary between laboratories based on antigen preparation, blot quality, and reader experience. This raised concerns about reproducibility and standardization.

Surveillance Criteria vs. Clinical Diagnosis

The CDC two-tier testing criteria were developed in 1994 for epidemiologic surveillance—not individual clinical diagnosis. Strict band-count rules were considered too rigid for genuine patient care, but laboratories were expected to follow them.

Push Toward Standardization

Enzyme immunoassays offered automation, standardization, and faster results compared to manual Western blot interpretation. Regulatory agencies favored these standardized approaches, leading to development of Modified Two-Tier Testing (MTTT) algorithms.

Early Infection Sensitivity

Western blot often remains negative in the first 2-4 weeks of infection and in patients treated early. Some studies suggested that C6/VlsE-based assays detected antibodies earlier than traditional Western blot.

---

The Impact on Patient Care

LabCorp’s policy created immediate problems for clinicians and patients.

Physicians who relied on Western blot testing for patients with negative screening tests but high clinical suspicion were forced to direct patients to other laboratories. This added delays, costs, and confusion to an already complex diagnostic process.

For patients in Lyme-endemic areas presenting with compatible symptoms but negative screening tests, the policy meant that confirmatory testing was simply unavailable through one of the nation’s largest laboratory networks.

The restriction highlighted a fundamental tension: laboratory policies designed for standardization and surveillance were being applied to individual patient care—where clinical judgment and diagnostic nuance matter most.

---

What Changed: Current Access to Western Blot Testing

LabCorp has since reversed this policy. Physicians can now order Western blot testing through LabCorp regardless of screening test results.

This change reflects recognition that clinical decision-making requires flexibility—particularly for infections like Lyme disease where testing limitations are well-documented and clinical presentation often precedes serologic confirmation.

The broader testing landscape has also evolved. Modified Two-Tier Testing (MTTT) protocols, cleared by the FDA beginning in 2019, offer an alternative to traditional ELISA-Western blot sequences. These use two enzyme immunoassays with different antigen targets rather than relying on Western blot confirmation.

However, Western blot remains available and continues to provide specific antigen reactivity information that some clinicians find valuable for diagnosis.

---

Why Testing Method Matters Less Than Clinical Judgment

Whether using traditional two-tier testing, Modified Two-Tier Testing, or direct Western blot ordering, one fundamental truth remains: all antibody-based tests depend on immune response.

No currently available test solves early seronegativity, immune suppression, antibiotic-altered responses, or interpretation of persistent symptoms. Changing testing methodology does not change the underlying biology of Borrelia infection or immune response timing.

This is why clinical diagnosis—based on symptoms, exposure history, and response to treatment—remains essential when laboratory results are negative or equivocal.

---

Frequently Asked Questions

Can I order a Western blot through LabCorp now?
Yes. LabCorp has reversed its 2014 policy restricting Western blot access. Physicians can now order Western blot testing regardless of screening test results.

Why was Western blot access restricted in the first place?
LabCorp restricted access due to concerns about test complexity, variability between laboratories, and movement toward standardized enzyme immunoassays. The policy aimed to enforce two-tier testing protocols.

Is Western blot more accurate than ELISA?
Western blot provides different information—specific antibody band patterns—rather than being inherently more accurate. Both tests detect antibodies, not active infection, and both can miss early Lyme disease.

What is Modified Two-Tier Testing?
Modified Two-Tier Testing uses two enzyme immunoassays with different antigen targets instead of ELISA followed by Western blot. It offers standardization and automation while maintaining two-tier confirmation.

Should I use Western blot or Modified Two-Tier Testing?
This is a clinical decision best made with your physician. Both approaches have limitations in early infection. Clinical judgment based on symptoms and exposure history remains essential regardless of testing method.

---

Clinical Takeaway

The LabCorp Western blot policy battle illustrates a larger truth about Lyme disease diagnosis: testing access matters, but testing limitations matter more. Whether using traditional Western blot or newer Modified Two-Tier protocols, all antibody-based tests share the same fundamental constraint—they depend on immune response timing. Early Lyme disease, the stage when treatment is most effective, is precisely when testing is least reliable. This is why the reversal of LabCorp’s restrictive policy was important. It restored physician autonomy to order confirmatory testing when clinical judgment warranted it. But it did not solve the underlying challenge: Lyme disease remains a clinical diagnosis that laboratory results support but cannot define. When symptoms and exposure history suggest infection, treatment should not wait for serology to catch up with biology.

---